Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Food and Drug Administration (FDA), the United States Department of Agriculture (USDA), United Nations University (UNU) and the United States National Academy of Sciences when judging the quality of protein in the human is not PER or BV but the Protein Digestibility Corrected Amino Acid Score (PDCAAS), as it is viewed as accurately measuring the correct relative nutritional value of animal and vegetable sources of protein in the diet.
=== Judgment-based === A metalloid is an element that possesses a preponderance of properties in between, or that are a mixture of, those of metals and nonmetals, and which is therefore hard to classify as either a metal or a nonmetal. This is a generic definition that draws on metalloid attributes consistently cited in the literature. Difficulty of categorisation is a key attribute. Most elements have a mixture of metallic and nonmetallic properties, and can be classified according to which set of properties is more pronounced. Only the elements at or near the margins, lacking a sufficiently clear preponderance of either metallic or nonmetallic properties, are classified as metalloids. Boron, silicon, germanium, arsenic, antimony, and tellurium are commonly recognised as metalloids. Depending on the author, one or more from selenium, polonium, or astatine are sometimes added to the list. Boron sometimes is excluded, by itself, or with silicon. Sometimes tellurium is not regarded as a metalloid. The inclusion of antimony, polonium, and astatine as metalloids has been questioned. Several other elements are occasionally classified as metalloids. These elements include hydrogen, beryllium, nitrogen, phosphorus, sulfur, zinc, gallium, tin, iodine, lead, bismuth, radon, flerovium, moscovium, livermorium, tennessine, and oganesson. However, due to relativistic effects and short half-lives, Fl to Og are hard to place into metalloids.
== Biography == Pierluigi Christophe Orunesu established Cybel’Art, a company that developed XR, digital and holographic protocol called icologram. His company collaborated with various artists, including Philippe Entremont and Henri Dès. In 2008 in Switzerland, Orunesu founded Eurolactis, a business focused on the processing and distribution of Donkey's milk. His company operates worldwide and has a research team in Italy. In 2011, Eurolactis signed a partnership agreement with football club Inter Milan. In 2017, he stepped down from the presidency, but remained involved as the general manager. In December 2014, he donated two donkey foals and freeze-dried donkey milk to Pope Francis, intended for the Vatican hospitals. In 2016, Pierluigi Christophe Orunesu collaborated with Swiss master chocolatier Gérard Fornerod to create "Quartier des Ânes," the first Swiss chocolate bar made with donkey milk, marking an unprecedented innovation in the history of Swiss chocolate-making. In 2020, Pierluigi Christophe Orunesu was invited to testify at the Agriculture and Agri-Food Commission of the Italian Senate as CEO of Eurolactis, in the context of Bill No. 1197 on the valorization of the Italian Donkey milk production chain. His expert testimony contributed to the legislative discussion aimed at increasing Donkey milk production for human consumption in Italy. In 2023, his company, Cybel’Art, launched icologram App, a digital and spatial computing startup that allows the virtual presence of artists, such as Henri Dès, through augmented reality technology.
=== Solvent affinity === Suspensions of nanoparticles are possible since the interaction of the particle surface with the solvent is strong enough to overcome density differences, which otherwise usually result in a material either sinking or floating in a liquid.
=== Composition === Amino acids: transported by ciliary muscles 98% water Electrolytes (pH = 7.4 -one source gives 7.1) Sodium = 142.09 Potassium = 2.2 - 4.0 Calcium = 1.8 Magnesium = 1.1 Chloride = 131.6 HCO3− = 20.15 Phosphate = 0.62 OSM = 304 Ascorbic acid Glutathione Immunoglobulins
Sources: en.wikipedia.org
== Bibliography == McNeill, A; Brose, LS; Calder, R; Bauld, L; Robson, D (February 2018). "Evidence review of e-cigarettes and heated tobacco products 2018" (PDF). UK: Public Health England. pp. 1–243. Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (January 2018). Stratton, Kathleen; Kwan, Leslie Y.; Eaton, David L. (eds.). Public Health Consequences of E-Cigarettes (PDF). National Academies of Sciences, Engineering, and Medicine (National Academies Press). pp. 1–774. Bibcode:2018nap..book24952N. doi:10.17226/24952. ISBN 978-0-309-46834-3. PMID 29894118. McNeill, A; Brose, LS; Calder, R; Hitchman, SC; Hajek, P; McRobbie, H (August 2015). "E-cigarettes: an evidence update" (PDF). UK: Public Health England. pp. 1–113. "Electronic Nicotine Delivery Systems and Electronic Non-Nicotine Delivery Systems (ENDS/ENNDS)" (PDF). World Health Organization WHO. August 2016. pp. 1–11. Wilder, Natalie; Daley, Claire; Sugarman, Jane; Partridge, James (April 2016). "Nicotine without smoke: Tobacco harm reduction". UK: Royal College of Physicians. pp. 1–191. "State Health Officer's Report on E-Cigarettes: A Community Health Threat" (PDF). California Tobacco Control Program. California Department of Public Health. January 2015. pp. 1–21. This article incorporates text from this source, which is in the public domain.
DNA-binding domain (DBD) A protein domain containing at least one structural motif capable of recognizing and interacting with the nucleotides of a double-stranded or single-stranded DNA molecule. DNA-binding domains may bind to specific sequences or have a non-specific affinity for DNA. They are the primary functional components of DNA-binding proteins, including many transcription factors and regulatory proteins.
While arginine, glutamine and other amino acids are rapidly consumed often very early in fermentation, proline is not consumed by yeast at all during the normal, anaerobic conditions of fermentations. This is because one of the enzymes required for its use is an oxidase (requiring molecular oxygen) and the other is repressed by the presence of ammonium (another source of assimilable nitrogen needed by yeast) in the must. However, well aerated starter cultures that contain must which hasn't had any diammonium phosphate added it to it will usually see some utilization of proline before the anaerobic conditions of fermentation kick in. When winemakers measure FAN, they need to be aware if their assay is including proline since this will make their YAN measurement higher. Chardonnay and Cabernet Sauvignon are two Vitis vinifera varieties that are known to have very high proline levels while Riesling and Sauvignon blanc usually have very low levels. Yeast transport amino acids and small peptides (less than 5 amino acid residues) into the cell via an active transport process that utilizes specialized membrane proteins and the difference in the pH gradient of the acidic wine solution (pH between 3-4) and the near neutral pH of cytoplasm inside the yeast cells. The proton symport proteins in the membrane take in the amino acid coupled with a hydrogen ion that later gets expelled by the cell via a hydrogen ion pump.
Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "Assessment report on Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014. Committee on Herbal Medicinal Products (HMPC) (22 May 2012). "List of references supporting the assessment of Citrus bergamia Risso et Poiteau, aetheroleum Final" (PDF). European Medicines Agency (EMA). Archived from the original (PDF) on 8 April 2014. Retrieved 7 April 2014.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.